Haemonetics Corp : Bofa Global Research Raises Price Objective To $90 From $75

Wednesday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Tesla (TSLA) are rallying, while stocks like Netflix (NFLX) are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers (Market Cap:$200 billion USD or higher)

• Netflix (NFLX); Comcast (CMCSA) bid to merge NBCUniversal unit with Warner Bros - Bloomberg; -5.97%
• Microsoft (MSFT); Microsoft Lowers AI Software Sales Quotas as Customers Resist Newer Products; -2.37%
• Micron Tech (MU); -1.95%
• Alibaba-exch (BABA); -2.04%
• Tesla Motors (TSLA); After AI Push, Trump Administration Is Now Looking To Robots; +2.76%

Large-Cap Stock Movers (Market Cap:$10-$200 billion USD)

• Pure Storage Inc (PSTG); Pure Storage posts in-line Q3 earnings, revenue beat; Shares fall 10%; -26.35%
• SanDisk Corp-Exch (SNDK); -6.5%
• Wayfair Inc (W); Jefferies downgrades Wayfair stock to Hold on valuation concerns; -5.65%
• UL Solutions (ULS); UL Solutions announces secondary offering of 12.5 million stocks; -5.37%
• Seagate Technology (STX); -5.41%
• Marvell Technology Group Ltd (MRVL); Summit Insights upgrades Marvell stock rating to Buy on AI growth outlook; +6.8%
• ON Semiconductor (ON); +6.2%
• Alcoa (AA); +5.77%
• Fiserv Inc (FISV); +4.81%
• Microchip Technology Inc (MCHP); Microchip unveils low-power digital monitors for battery devices; +8.64%

Mid-Cap Stock Movers (Market Cap:$2-$10 billion USD)

• Gitlab (GTLB); GitLab appoints Jessica Ross as new CFO effective January 2026; -15.03%
• Adaptive Biotechnologies Corp (ADPT); -9.5%
• Diginex Inc (DGNX); -10.0%
• Fermi America LLC (FRMI); -6.66%
• ELF Beauty Inc (ELF); +8.05%
• dMY Technology Group II (GENI); +8.75%
• Regencell Bioscience Holdings (RGC); +8.1%
• American Eagle Outfitters (AEO); American Eagle stock soars 11% on strong Q3 results, raised guidance; +13.97%
• SeaCube Container Leasing Ltd (BOX); Box Inc stocks plunge over 10% on bottom-line miss in Q3; +7.29%
• MTech Acquisition A (ABTC); +6.16%

Small-Cap Stock Movers (Market Cap:$300 million - $2 billion USD)

• Ambitions Enterprise Management Co (AHMA); +43.51%
• MapLight Therapeutics Inc (MPLT); +26.38%
• Anavex Life Sciences (AVXL); +23.21%
• InterPrivate Acquisition (AEVA); European automaker selects Aeva as exclusive lidar supplier; +17.4%
• Pharvaris BV (PHVS); Pharvaris reports positive phase 3 results for HAE attack treatment; +17.0%
• Carbylan Therapeutics Inc (KALV); +17.38%
• POET Tech NAQ (POET); +13.93%
• TryHard Holdings (THH); -19.71%
• Acadia Healthcare (ACHC); Acadia Healthcare stock rating downgraded by BofA on higher insurance costs; -14.68%
• Adc Therapeutics SA (ADCT); ZYNLONTA-glofitamab combo shows 90% response rate in lymphoma trial; -29.35%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Pharvaris N.V. (NASDAQ:PHVS) stock jumped 20% after the company announced positive topline results from its pivotal Phase 3 RAPIDe-3 study for deucrictibant, an oral treatment for hereditary angioedema (HAE) attacks.

The late-stage biopharmaceutical company reported that the study met its primary endpoint, with patients experiencing median time to onset of symptom relief in 1.28 hours compared to over 12 hours for placebo. All 11 secondary efficacy endpoints also achieved statistical significance, showing faster symptom relief and earlier complete symptom resolution compared to placebo.

Deucrictibant demonstrated a median time to End of Progression of 17.47 minutes versus 228.67 minutes for placebo, and median time to complete symptom resolution of 11.95 hours compared to over 24 hours for placebo. The oral treatment also showed efficacy across all HAE subtypes and varying attack severities and locations.

The study enrolled 134 participants from 24 countries, including adolescents and adults with different HAE types. Notably, 83% of attacks were treated with a single capsule of deucrictibant, and 93.2% of treated attacks did not require rescue medication.

Marc A. Riedl, principal investigator in the RAPIDe-3 study, noted, "Bradykinin B2 receptor antagonism is a proven and effective mechanism for treatment of bradykinin-mediated angioedema. Injectable and oral on-demand therapies for HAE are available, however unmet medical needs remain. Effective, well-tolerated, and convenient acute treatment is an essential part of all HAE management plans due to unpredictable angioedema symptoms. The comprehensive and compelling outcomes of RAPIDe-3, specifically the fast treatment response and early complete symptom resolution, demonstrate the potential benefits of deucrictibant as an important on-demand treatment for people living with HAE."

Pharvaris plans to file marketing authorization applications starting in the first half of 2026, with a New Drug Application submission to the FDA on track for the same timeframe.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com — With ADP job market data approaching and the broader market shifting rapidly between optimism and bubble fears, many investors are uncertain about how to prepare for the weeks ahead. In conditions like these, data-driven analytics separate those who chase the market’s direction from those who position themselves strategically and focus on overlooked opportunities.

Our December lineup of AI-powered stock picks has already uncovered several big winners, even though it has only been live since Monday:

• Coronado Global Resources Inc (NASDAQ:CRDO): +19.64% in December alone
• Lumen Technologies Inc (NASDAQ:LUMN): +10.25% in December alone
• Verusa Holding AS (IS:VERUS): +20.93% in December alone
• Kolon Industries Inc (KOSDAQ:002020): +10.84% in December alone

After gains like these in just two days, our members are looking forward to more double-digit moves this month.

*InvestingPro members can click here to jump straight to our new list of stock picks.

Still not a member? Then this is your chance to subscribe at up to 55% off and secure access to the top picks for December.

• Reading this on our app? Subscribe here
• Reading this on desktop? Subscribe here

More than 250.000 investors trust InvestingPro when it comes to picking the right stocks and the results speak for themselves. Take a look at how some of our highest conviction picks performed in November:

• Haemonetics (NYSE:HAE): +62.67% in November alone
• Kohl’s Corp (NYSE:KSS): +51.14% in November alone
• Holley (NYSE:HLLY): +48.43% in November alone
• Seers Technology (KQ:458870): +68.75% in November alone

Our AI-powered stock picks don’t just focus on single-month trends in the stock market. Our has also been able to determine when to hold on to exceptional winners, like these:

• ViaSat Inc (NASDAQ:VSAT): +163% after picked by our AI.
• Thyssenkrupp (OTC:TKAMY) (ETR:TKAG): +223% after picked by our AI.
• ABL Bio Inc (KQ:298380): +170% after picked by our AI.
• Colab Cloud Platforms (BO:COLA): +111% after picked by our AI.
• Banco : +104% after picked by our AI.

Among several others...

But how does the AI behind these picks actually work?

At the start of each month, the AI refreshes every strategy with up to 20 new stock picks, analyzing more than 150 investor-grade financial models built on over 15 years of global market data. It identifies where risk and reward align best — removing underperformers, keeping promising names, and adding fresh opportunities. Each decision is backed by a rationale that clarifies why a stock was added, removed, or kept in the strategy.

The strategies use equal weighting across all selected stocks, creating a transparent and consistent way to track results. The goal is not just to find winners, but also to know when to move on from the ones that stop performing.

Check out the 12-year outperformance of Tech Titans over the S&P 500 below:

This means a $100K principal in our strategy would have turned into an eye-popping $2,649,600.

Disclaimer: Prices mentioned in articles are accurate at the time of publication. We regularly test different offers for our members, which may vary by region.

Investing.com -- As 2025 draws to a close amid a whirlwind of AI-bubble worries and shifting interest-rate expectations, investors are all asking the same thing: How do I position my portfolio for 2026?

Join Asaf Rothem (VP of Marketing), Thomas Monteiro (Head of Financial Content), Lon Juricic (VP of News), and Ricky Gutierrez (Influencer Guest) in this exclusive live webinar, where they will reveal Investing.com’s Top 10 Stock Picks for 2026.

The webinar will go live at 9:00 a.m. ET on December 2nd.

The team will deliver a deep analysis of market trends, uncover where the next major opportunities may be hiding, and share their highest conviction stock ideas for the year ahead.

Our top 10 stock picks for 2025 delivered an average return of +27.02% this year, outperforming the S&P 500 by +13.58% over the same period. HALF of the selected stocks gained more than 40%, and four surged more than 50%.

Here is the updated performance list of our top stocks for 2025:

• Monolithic Power Systems, Inc: +51.60%
• Applied Materials, Inc.: +40.63%
• J.B. Hunt Transport Services, Inc.: -6.07%
• HCA: +58.95%
• Lockheed Martin Corporation: -3.12%
• LPL Financial Holdings Inc.: +10.69%
• Fortinet, Inc.: -13.27%
• IDEX Corporation: -22.23%
• KLA Corporation: +79.92%
• Intel Corporation: +73.12%

Our top 10 picks were generated with the same AI models that power our premium investor-grade stock picker on a monthly basis. Since the start of the year, our AI has picked fantastic winners, such as:

• Haemonetics (NYSE:HAE): +62.67% in November ALONE
• Kohl’s Corp (NYSE:KSS): +51.14% in November ALONE
• Holley (NYSE:HLLY): +48.43% in November ALONE
• Seers Technology (KQ:458870):+68.75% in November ALONE
• ViaSat Inc (NASDAQ:VSAT): +163% after picked by our AI.
• Thyssenkrupp (OTC:TKAMY) (ETR:TKAG): +223% after picked by our AI.
• ABL Bio Inc (KQ:298380): +170.30% after picked by our AI.
• Banco (BME:SAN): +104.45% after picked by our AI.
• Colab Cloud Platforms (BO:COLA): +111.80% after picked by our AI.

Among several others...

Not yet a member? Then here’s your chance to use the last day of our Cyber Monday Sale to get InvestingPro for the LOWEST PRICE OF THE YEAR at up to 60% off.

Investing.com -- As the broader market experienced significant volatility in November due to shifting interest rate expectations and growing concerns about AI overvaluation, the best opportunities appeared beyond the mega-cap space.

In fact, the broader repricing of the AI trade meant that capital moved from year-to-date winners such as Oracle, Palantir, Microstrategy, and Nvidia toward earlier-stage, higher-growth names across the small- and mid-cap spaces.

As a result, those able to spot the right opportunities outperformed the market by a wide margin.

Such was the case of our InvestingPro members, who, for less than $7 a month (, received a list of AI-picked names at the start of the month with winners such as:

• Haemonetics (NYSE:HAE): +62.67% in November ALONE
• Kohl’s Corp (NYSE:KSS): +51.14% in November ALONE
• Holley (NYSE:HLLY): +48.43% in November ALONE
• Seers Technology (KQ:458870):+68.75% in November ALONE

Among several others...

Not only that, but our AI’s composed small-cap-focused list of picks gained a massive +9.15% while the S&P 500 lost -0.38% and the Russel 2000 shed -0.45%. That’s a near 10% outperformance over the market in November alone.

Longer term, the results are even greater, with our list of tech picks gaining a game-changing +148.26% since launch in November 2023 (two years ago).

Not only that, but our AI has also surfaced even greater individual wins. Here are some of the CRAZY winners picked by the AI this year:

• ViaSat Inc (NASDAQ:VSAT): +163% after picked by our AI.
• Thyssenkrupp (OTC:TKAMY) (ETR:TKAG): +223% after picked by our AI.
• ABL Bio Inc (KQ:298380): +170.30% after picked by our AI.
• Banco (BME:SAN): +104.45% after picked by our AI.
• Colab Cloud Platforms (BO:COLA): +111.80% after picked by our AI.

*These are real-world results, recorded since the official launch of our AI-powered models.

The secret? Superior stock picking, based on investor-grade financial models compiled by our AI model and applied to all stocks in the market.

But if you missed these picks, here’s the good news: a FRESH list of stock picks for December is already OUT.

InvestingPro members can jump straight to the list here.

Still not a member? Then take advantage of the lowest price of the year FOR TODAY ONLY.

Spoiler alert: Even after rallying +62.67% in November, Haemonetics stayed on the list of picks for December.

But ProPicks AI doesn’t only pick US stocks. In fact, since the start of the year, our AI has been notching arguably greater results across the world, in both developed and developing markets alike.

Here are more global stats on the performance of our AI’s stock picks:

• 92.05% of strategies are profitable
• 68 winning strategies recorded an average profit of 31.1%.
• 50 strategies managed to break the 20 percent mark.
• The best strategy gained 62.38% this year.
• The largest outperformance is 43.24% over the benchmark this year.
• 73.86% of the strategies outperform their benchmark indices by an average of 12.65%.

Here’s More on How the AI Models Works

At the start of each month, our AI refreshes each strategy with up to 20 stock picks. These selections are based on a blend of more than 150 well-established financial models compiled by our machine learning model on over 15 years of financial data worldwide.

Some stocks are added, others retained, and a few are removed, reflecting how the model reassesses each company’s medium-term growth potential.

To track performance, each strategy uses equal weighting across all selected stocks. While you’re not required to follow that weighting exactly, it offers a consistent benchmark to evaluate how well the model identifies opportunities across the board.

At the end of the day, stock picking is still a game of probabilities. But the key isn’t just finding winners — it’s knowing when to move on from the ones that no longer stack up.

Since launch, the model has done just that — delivering more than a few standout success stories along the way.

Disclaimer: Prices mentioned in articles are accurate at the time of publication. We regularly test different offers for our members, which may vary by region.